Press Releases and Blog
Blog
ICYMI: RealClearHealth: Pat Toomey: Attacking PBMs Won’t Solve President Biden’s Inflation Problem
In case you missed it, former U.S. Senator Pat Toomey (R-PA) explains how the Biden Administration’s recent push targeting pharmacy benefit companies is a deflecting
ICYMI: Ike Brannon: Recently Proposed Federal And State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed
Misguided Proposals Targeting Pharmacy Benefit Companies Would Increase Prescription Drug Costs for Patients, Take Away Options From Health Plan Sponsors, Like Employers and Unions
Proponents of policies targeting pharmacy benefit companies ignore the costly repercussions of undermining pharmacy benefit managers’ (PBMs) ability to secure savings that enable health plan
Renewed Congressional Focus On Patent Abuse Touts Proposals to Effectively Lower Prescription Drug Costs, Strengthen Competition in the Market
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent
ICYMI: 2021 House Oversight Committee Report Concluded Rebates Are Uncorrelated With Drug Prices
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with
ICYMI: Former U.S. Senator Pat Toomey: GOP Can’t Afford to Start 2024 with Giant Health Care Mandates
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated
Press Releases
National Bureau of Economic Research Working Paper: “Delinking” Proposals that Restrict PBM Incentives to Secure Rx Savings Will Increase Drug Prices and Provide $10B Giveaway for Big Pharma
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “Ending Pay for PBM Performance: Consequences
PCMA Statement on Legislation Introduced in the House of Representatives
(Washington, D.C.) — PCMA issued the following statement on legislation introduced in the House of Representatives: Legislation introduced in U.S. House of Representatives targeting pharmacy
PCMA Statement on the Tenth Circuit’s Decision in PCMA v. Mulready
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the recent ruling by the U.S. Court of Appeals for the Tenth Circuit in PCMA
PCMA Statement on House Ways and Means Committee and Senate Finance Committee Legislation
What Problem is Congress Trying to Solve? (Washington D.C.) – The Pharmaceutical Care Management Association released the following statement on today’s votes in the Senate
PCMA Statement on Federal Trade Commission Vote on PBM Advocacy
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote by the Federal Trade Commission (FTC): “We agree with
PCMA Statement On House Education And The Workforce Committee, Subcommittee On Health, Employment, Labor, And Pensions Hearing
PCMA President and CEO Testifying Today on Importance of Preserving Employer Choice and Contracting Flexibility (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released
ICYMI: JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a paper,
Current And Former Policymakers, Experts Agree Anti-PBM Bills Restrict Free Market, Would Do Nothing To Lower Rx Drug Costs
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers
ICYMI: PCMA Rx Research Corner: In Their Pharmacy Benefit Company Relationships, Employers Have Choice, Flexibility, And The Final Say
In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress
Anti-PBM Bills Would Take Away the Choice and Flexibility Employers Say They Value
Employers overwhelmingly say they’re satisfied with their PBM, describe PBM contracts as “transparent,” and value a wide range of choices from their PBMs A recent
ICYMI: Policymakers And Expert Panel Highlight Negative Consequences Of Misguided Policies Targeting Pharmacy Benefits
In case you missed it, last week’s RealClearPolitics’ virtual event, “The Consequences of Targeting Pharmacy Benefits,” featured policymakers and expert voices exploring the potential negative
Reminder: Conservative Thought Leaders And GOP Lawmakers Oppose Anti-PBM Government Mandates
The U.S. House of Representatives is preparing a suspension vote on the Lower Costs, More Transparency Act, which includes many of the controversial, overreaching proposals
Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: JC Scott In RealClearHealth: Amid Rising Health Care Premiums, Misguided Legislation Would Raise Costs Even Higher
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting
ICYMI: Former U.S. Senator Pat Toomey: Before Targeting PBMs, Republicans Should Consider The Unintended Consequences
In case you missed it, Pat Toomey, former U.S. Senator from Pennsylvania, cautioned lawmakers against legislation targeting pharmacy benefit companies and policies that meddle with
New JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a new